- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs.
SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs.
Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target.
"We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical's pipeline", said Jens Frauenfeld, CEO of Salipro Biotech. "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable."
Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts."
About Salipro Biotech AB
Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins.
The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design.
To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs.
About Daewoong Pharmaceutical
Daewoong Pharmaceutical (KRX: 069620.KS), established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities.
Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
|
NAIROBI, Kenya and NEWPORT BEACH, Calif., Jan. 16, 2026 /PRNewswire/ -- The Open University of Kenya (OUK) and MindHYVE.ai, Inc., a U.S.-based artificial intelligence company, have signed a Memorandum of Understanding (MoU) establishing a strategic collaboration focused on advancing AI-powered learning enablement and academic innovation.
The collaboration explores the integration of ArthurAI™, MindHYVE.ai's proprietary agentic artificial intelligence system, into selected areas of OUK's digital learning ecosystem. The initiative is designed to support personalized learning, faculty enablement, data-driven curriculum innovation and workforce-aligned upskilling, positioning OUK as a leader in next-generation digital education across Africa.
Under the MoU, the parties will jointly explore implementation of ArthurAI as a virtual academic enabler, supporting learners and educators through adaptive, real-time learning assistance. The collaboration also includes curriculum co-design, impact evaluation, localization aligned with Kenya's education policy and adherence to the Kenya Data Protection Act (2019).
"This collaboration reflects the Open University of Kenya's commitment to innovation, access and academic excellence," said Professor Elijah Omwenga, Vice-Chancellor of the Open University of Kenya. "By exploring responsible AI-powered learning systems, we aim to enhance student success, empower faculty and strengthen Kenya's position as a digital education leader."
"OUK represents a bold and forward-looking model for higher education in the digital age," said Bill Faruki, Founder and CEO at MindHYVE.ai™. "This collaboration allows us to responsibly explore how agentic AI can support learning, teaching and workforce readiness—while maintaining transparency, ethics and local relevance."
This collaboration reflects a shared vision to advance responsible AI in education, expand access to high-quality digital learning and support Kenya's broader goals for workforce development and innovation.
About The Open University of Kenya
The Open University of Kenya (OUK), established by Charter in August 2023, is Kenya's first fully online specialised public University. OUK is mandated to expand access to affordable, flexible, self-paced, inclusive and high-quality higher education through digital and open learning innovation. It offers Professional Development Courses, Undergraduate and Postgraduate Programmes designed to meet the needs of learners across Kenya and beyond.
Website: https://ouk.ac.ke/ ∕ Email: info@ouk.ac.ke ∕ Contact: +254 703 211 211
Media Contact:
Brendah Kabindio
Email: bkabindio@ouk.ac.ke
About MindHYVE.ai™
MindHYVE.ai™ is redefining the boundaries of intelligence by engineering autonomous systems and deploying domain-specific AGI agents across real-world sectors. Powered by the Ava-Fusion™ large reasoning model and architected for agent coordination, swarm intelligence, and adaptive autonomy, MindHYVE's technology stack is revolutionizing law, medicine, finance, education, and governance.
With operations in North America, Asia, and Africa, MindHYVE.ai™ is on a mission to democratize access to transformative intelligence and architect the infrastructure for post-scarcity economies. Backed by HYVE Labs, the company continues to shape the future of agentic systems on a global scale.
Website: www.mindhyve.ai | Email: hello@mindhyve.io | Contact: +1 (949) 200-8668
Media Contact:
Marc Ortiz
Email: marc.ortiz@mindhyve.io
NAIROBI, Kenya and NEWPORT BEACH, Calif., Jan. 16, 2026 /PRNewswire/ -- The Open University of Kenya (OUK) and MindHYVE.ai, Inc., a U.S.-based artificial intelligence company, have signed a Memorandum of Understanding (MoU) establishing a strategic collaboration focused on advancing AI-powered learning enablement and academic innovation.
The collaboration explores the integration of ArthurAI™, MindHYVE.ai's proprietary agentic artificial intelligence system, into selected areas of OUK's digital learning ecosystem. The initiative is designed to support personalized learning, faculty enablement, data-driven curriculum innovation and workforce-aligned upskilling, positioning OUK as a leader in next-generation digital education across Africa.
Under the MoU, the parties will jointly explore implementation of ArthurAI as a virtual academic enabler, supporting learners and educators through adaptive, real-time learning assistance. The collaboration also includes curriculum co-design, impact evaluation, localization aligned with Kenya's education policy and adherence to the Kenya Data Protection Act (2019).
"This collaboration reflects the Open University of Kenya's commitment to innovation, access and academic excellence," said Professor Elijah Omwenga, Vice-Chancellor of the Open University of Kenya. "By exploring responsible AI-powered learning systems, we aim to enhance student success, empower faculty and strengthen Kenya's position as a digital education leader."
"OUK represents a bold and forward-looking model for higher education in the digital age," said Bill Faruki, Founder and CEO at MindHYVE.ai™. "This collaboration allows us to responsibly explore how agentic AI can support learning, teaching and workforce readiness—while maintaining transparency, ethics and local relevance."
This collaboration reflects a shared vision to advance responsible AI in education, expand access to high-quality digital learning and support Kenya's broader goals for workforce development and innovation.
About The Open University of Kenya
The Open University of Kenya (OUK), established by Charter in August 2023, is Kenya's first fully online specialised public University. OUK is mandated to expand access to affordable, flexible, self-paced, inclusive and high-quality higher education through digital and open learning innovation. It offers Professional Development Courses, Undergraduate and Postgraduate Programmes designed to meet the needs of learners across Kenya and beyond.
Website: https://ouk.ac.ke/ ∕ Email: info@ouk.ac.ke ∕ Contact: +254 703 211 211
Media Contact:
Brendah Kabindio
Email: bkabindio@ouk.ac.ke
About MindHYVE.ai™
MindHYVE.ai™ is redefining the boundaries of intelligence by engineering autonomous systems and deploying domain-specific AGI agents across real-world sectors. Powered by the Ava-Fusion™ large reasoning model and architected for agent coordination, swarm intelligence, and adaptive autonomy, MindHYVE's technology stack is revolutionizing law, medicine, finance, education, and governance.
With operations in North America, Asia, and Africa, MindHYVE.ai™ is on a mission to democratize access to transformative intelligence and architect the infrastructure for post-scarcity economies. Backed by HYVE Labs, the company continues to shape the future of agentic systems on a global scale.
Website: www.mindhyve.ai | Email: hello@mindhyve.io | Contact: +1 (949) 200-8668
Media Contact:
Marc Ortiz
Email: marc.ortiz@mindhyve.io
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
MindHYVE.ai™ and The Open University of Kenya Announce Strategic Collaboration on AI-Powered Learning and Academic Innovation
